AMGN AMGEN Inc.

$AMGN should help the $IBB cohort Monday. AI long term will benefit the biotech sector w/discovery and regulatory admin etc it's going to finally give tech ETF's something to compete with. $QQQ

$AMGN I bought this stock a few years back when my niece started working there. I figured if they were smart enough to hire her, the company would do alright. And they have.

$AMGN installed David W. Gibbs to its Board, where he'll serve on the Audit and Compensation & Management Development committees.

$AMGN: A potential breakthrough in aggressive lung cancer—and a major growth opportunity. Amgen’s IMDELLTRA, combined with AstraZeneca’s $AZN IMFINZI, cut the risk of death by 58% in a Phase 3 trial of patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months vs. 12.7 months with IMFINZI alone—an 8.4-month improvement. Nearly 80% of patients receiving the combination were alive at one year, vs. 53% on IMFINZI alone. (Source: CNBC)

$AMGN demonstrated strong Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with ~68% histologic remission at week 24.

$AMGN IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER "Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine"

$AMGN Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer https://www.cnbc.com/2026/10/24/amgen-imdelltra-lung-cancer-data.html?__source=iosappshare%7Ccom.google.chrome.ios.OpenExtension

$AMGN · $AZN 🏥 Amgen announced interim Phase 3 DeLLphi-305 results showing IMDELLTRA plus AstraZeneca's IMFINZI reduced the risk of death by 58% versus IMFINZI alone in first-line extensive-stage small cell lung cancer, with nearly 80% of patients alive at one year versus 53%. Selected from hundreds of headlines

$AMGN and $BIIB absolute beasts! Its all about their pipelines, strategic positioning in global context, and reliable business strength. Investors now are eager to put their money on the future winners across all sectors. These are my top large cap healthcare picks.

14 days out on $AMGN and this one is hiding in plain sight imo Nov 11 at ACR, late breaking abstract 22, dazodalibep Phase 3 OASIZ 301 in Sjogren disease Week 48 disease activity fell 5.6 points on the every 4 week dose vs 3.8 on placebo, p less than 0.001, and dryness improved too no FDA approved medicine exists for Sjogren right now closed Tuesday at 447.95, trading higher today and printing a new 52 week high a large cap with a real date and a real readout behind it ngl

$AMGN UBS upgraded Amgen to Buy on Friday, lifting its target to 470 from 430. That implies about 13% upside from the 414.87 close (per MarketBeat). The street has not caught up to the tape. Consensus is still a Hold, with an average target of 389.71, about 6% below the share price. UBS's 470 is now the high end of the board. Amgen closed Friday up about 2% and is up about 27% this year. The 52-week high is 447.03.

$AMGN up 2.5% after a price-target hike to $380 from $362 at Truist. Amgen stock is now 26% higher on the year and boasts a nearly 40% year-over-year gain the 80-day moving average provided a springboard last month